A carregar...
PARP inhibitor re-sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis
Resistance to Adriamycin (ADR) is an increasing problem in the treatment of leukemia and the development of novel therapeutic strategies is becoming increasingly important. Olaparib is a poly (adenosine diphosphate-ribose) polymerase (PARP) 1 inhibitor, which has promising antitumor activity in pati...
Na minha lista:
| Publicado no: | Mol Med Rep |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
D.A. Spandidos
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6297734/ https://ncbi.nlm.nih.gov/pubmed/30431088 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mmr.2018.9628 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|